Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present clinical data on CTP-543 for the treatment of alopecia areata as a late-breaker oral presentation at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress. The meeting will be held virtually October 29-31, 2020. The oral presentation will highlight new data from an ongoing open label extension study evaluating long-term safety and treatment effects of CTP-543 in patients with moderate to severe alopecia areata.
The details of the presentation are as follows:
Title: Initial Results from a Long-Term, Open-Label Extension Study with CTP-543, an Oral Janus Kinase Inhibitor, in Patients with Moderate to Severe Alopecia Areata
Date and Time: Thursday, October 29, 2020, 3:00 – 3:15 pm Central European Time
Session: D1T03.3C: Late-Breaking News Session
Location: EADV Virtual Meeting. Registration is required to participate: https://eadvvirtualcongress.org/registration/
About CTP-543 and Alopecia Areata
CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The U.S. Food and Drug Administration (FDA) has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata. The Company expects to begin Phase 3 evaluation of CTP-543 in the fourth quarter of 2020. Additional information on the upcoming trial is available on www.clinicaltrials.gov.
Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 700,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious